← Back to Search

Radioactive Material

TheraSphere® treatment for Liver Cancer (TheraSphere Trial)

N/A
Waitlist Available
Led By Nadine Abi-Jaoudeh, MD
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years.
Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0 - 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

TheraSphere Trial Summary

This trial is for patients with liver cancer who can't be treated surgically. The effects of TheraSphere on the tumor and any side effects will be examined.

Who is the study for?
This trial is for adults over 18 with unresectable hepatocellular carcinoma, a type of liver cancer. Candidates must have either a confirmed diagnosis or certain clinical indicators like a liver mass and elevated tumor markers. They should be able to perform daily activities with little to no assistance (ECOG score 0-2) and understand the study details.Check my eligibility
What is being tested?
The TheraSphere treatment is being tested, which involves injecting tiny glass beads containing radioactive Yttrium-90 into the liver's blood vessels. This targets the tumor directly with radiation while minimizing exposure to healthy tissue. The effects on tumors and potential side effects are studied at University California Irvine Medical Center.See study design
What are the potential side effects?
Possible side effects include those typically associated with radiation therapy such as fatigue, nausea, abdominal pain, and potential damage to surrounding healthy liver tissue. Since this is targeted therapy, risks of systemic side effects are reduced.

TheraSphere Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I can take care of myself and am up and about more than half of the day.
Select...
My cancer cannot be removed with surgery.

TheraSphere Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival Rate
Secondary outcome measures
Evaluate for side effects

TheraSphere Trial Design

1Treatment groups
Experimental Treatment
Group I: TheraSphere® treatmentExperimental Treatment1 Intervention
TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TheraSphere
2007
Completed Early Phase 1
~2150

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
544 Previous Clinical Trials
1,923,043 Total Patients Enrolled
BTG International Inc.OTHER
42 Previous Clinical Trials
3,086 Total Patients Enrolled
5 Trials studying Liver Cancer
29 Patients Enrolled for Liver Cancer
Nadine Abi-Jaoudeh, MDPrincipal InvestigatorUniversity of California, Irvine
4 Previous Clinical Trials
228 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma
Nadine Abi-Jaoudeh 2024. "TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00906984.
All > Liver Cancer > Hepatocellular Carcinoma
~233 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top